A Randomized, Double Blinded, Positive Controlled Phase Ⅰb Clinical Trial in Participants Aged 2 Months (42-89 Days) and 2 to 5 Years to Evaluate the Safety and Immunogenicity of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 15 Jul 2025 to 21 Jul 2025.
- 17 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2024 Planned End Date changed from 15 Apr 2025 to 15 Jul 2025.